Abiopharma

🔍 Simanovsky Michael (Executive)

Company: SONIDA SENIOR LIVING, INC. (SNDA)

Report Date: 2026-03-11

Detailed Transactions and Holdings:

• Acquired 1,592,406 shares of Common Stock at $26.74 per share (Direct)
  Date: 2026-03-11 | Code: P | equity_swap_involved: 0 | shares_owned_after: 3,199,998.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 87,530 shares of Common Stock at $26.74 per share (Direct)
  Date: 2026-03-11 | Code: P | equity_swap_involved: 0 | shares_owned_after: 5,353,689.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 224,829 shares of Common Stock at $26.74 per share (Direct)
  Date: 2026-03-11 | Code: P | equity_swap_involved: 0 | shares_owned_after: 224,829.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 1,834,951 shares of Common Stock at $26.74 per share (Direct)
  Date: 2026-03-11 | Code: P | equity_swap_involved: 0 | shares_owned_after: 1,834,951.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 1,504,134 shares of Common Stock at $32.0 per share (Direct)
  Date: 2026-03-11 | Code: M | equity_swap_involved: 0 | shares_owned_after: 6,857,823.00 | transaction_form_type: 4 | Footnotes: F4
• Acquired 97,371 shares of Common Stock at $32.0 per share (Direct)
  Date: 2026-03-11 | Code: M | equity_swap_involved: 0 | shares_owned_after: 807,115.00 | transaction_form_type: 4 | Footnotes: F5
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-11 | Code: H | nature_of_ownership: See footnotes | shares_owned_after: 1,032,216.00 | Footnotes: F5
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-11 | Code: H | nature_of_ownership: See footnotes | shares_owned_after: 648,942.00 | Footnotes: F5
• Acquired 1,203,308 shares of Series A Convertible Preferred Stock at $40.0 per share (Derivative)
  Date: 2026-03-11 | Code: D | Exercise: 2021-11-03 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F12, F11, F4
• Acquired 77,897 shares of Series A Convertible Preferred Stock at $40.0 per share (Derivative)
  Date: 2026-03-11 | Code: D | Exercise: 2021-11-03 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F12, F11, F5
• Acquired 1,504,134 shares of Series A Convertible Preferred Stock at $32.0 per share (Derivative)
  Date: 2026-03-11 | Code: A | Exercise: 2026-03-11 | equity_swap_involved: 0 | shares_owned_after: 38,742.00 | transaction_form_type: 4 | Footnotes: F12, F11, F4
• Acquired 97,371 shares of Series A Convertible Preferred Stock at $32.0 per share (Derivative)
  Date: 2026-03-11 | Code: A | Exercise: 2026-03-11 | equity_swap_involved: 0 | shares_owned_after: 2,508.00 | transaction_form_type: 4 | Footnotes: F12, F11, F5
• Acquired 1,504,134 shares of Series A Convertible Preferred Stock at $32.0 per share (Derivative)
  Date: 2026-03-11 | Code: M | Exercise: 2026-03-11 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F11, F4
• Acquired 97,371 shares of Series A Convertible Preferred Stock at $32.0 per share (Derivative)
  Date: 2026-03-11 | Code: M | Exercise: 2026-03-11 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F11, F5
• Acquired 968,538 shares of Warrant at $40.0 per share (Derivative)
  Date: 2026-03-11 | Code: D | Expires: 2026-11-03 | Exercise: 2021-11-03 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F12, F4
• Acquired 62,712 shares of Warrant at $40.0 per share (Derivative)
  Date: 2026-03-11 | Code: D | Expires: 2026-11-03 | Exercise: 2021-11-03 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F12, F5
• Acquired 968,538 shares of Warrant at $40.0 per share (Derivative)
  Date: 2026-03-11 | Code: A | Expires: 2027-11-03 | Exercise: 2026-03-11 | equity_swap_involved: 0 | shares_owned_after: 968,538.00 | transaction_form_type: 4 | Footnotes: F12, F4
• Acquired 62,712 shares of Warrant at $40.0 per share (Derivative)
  Date: 2026-03-11 | Code: A | Expires: 2027-11-03 | Exercise: 2026-03-11 | equity_swap_involved: 0 | shares_owned_after: 62,712.00 | transaction_form_type: 4 | Footnotes: F12, F5

Footnotes:

• F1: This Form 4 is being filed jointly by Michael Simanovsky, a United States citizen; Conversant Capital LLC, a Delaware limited liability company ("Conversant Capital"); Conversant GP Holdings LLC, a Delaware limited liability company ("Conversant GP"); Conversant Dallas Parkway (A) LP, a Delaware limited partnership ("Investor A"); Conversant Dallas Parkway (B) LP, a Delaware limited partnership ("Investor B"); Conversant Private GP LLC, a Delaware limited liability company ("Conversant Private GP") and Conversant PIF Aggregator A LP, a Delaware limited partnership ("Aggregator A") (collectively the filing persons are the "Reporting Persons").
• F2: Securities are held by Aggregator A.
• F3: Conversant Private GP is the general partner of Aggregator A, CPIF K Co-Invest SPT A, L.P., a Cayman Islands exempted limited partnership ("CPIF K") and CPIF Sparti SAF, L.P., a Delaware limited partnership ("CPIF SAF") and Conversant Capital is the investment manager to Aggregator A, CPIF K and CPIF SAF. Mr. Simanovsky is the managing member of Conversant Capital and Conversant Private GP. By virtue of these relationships, each of Mr. Simanovsky, Conversant Capital and Conversant Private GP may be deemed a beneficial owner of the securities held by Aggregator A, CPIF K and CPIF SAF. Mr. Simanovsky, Conversant Capital and Conversant Private GP, each disclaims beneficial ownership of the securities held by Aggregator A, CPIF K and CPIF SAF except to the extent of his or its pecuniary interest therein.
• F4: Securities are held by Investor A.
• F5: Conversant GP is the general partner of each of Investor A, Investor B, Conversant Dallas Parkway (D) LP, a Delaware limited partnership ("Investor D") and Conversant Dallas Parkway (F) LP, a Delaware limited partnership ("Investor F"). Conversant Capital is the investment manager to each of Investor A, Investor B, Investor D and Investor F. Mr. Simanovsky is the managing member of Conversant Capital and Conversant GP. By virtue of these relationships, each of Mr. Simanovsky, Conversant Capital and Conversant GP may be deemed a beneficial owner of the securities held by each of Investor A, Investor B, Investor D and Investor F. Mr. Simanovsky, Conversant Capital, and Conversant GP each disclaims beneficial ownership of the securities held by Investor A, Investor B, Investor D and Investor F except to the extent of his or its pecuniary interest therein.
• F6: Securities are held by Investor B.
• F7: Securities are held by Investor D.
• F8: Securities are held by Investor F.
• F9: Securities are held by CPIF K.
• F10: Securities are held by CPIF SAF.
• F11: There is no expiration date for the right of the holder of Series A Convertible Preferred Stock to convert.
• F12: On March 11, 2026, the Issuer agreed with each of Investor A and Investor B to (i) amend the shares of Series A Convertible Preferred Stock to reduce the conversion price to $32 per share of Common Stock, (ii) make a onetime payment of approximately $5.8 million in the aggregate, which included approximately $1.1 million of accrued but unpaid dividends for the period of January 1, 2026 through March 11, 2026, to Investor A and Investor B pro rata in accordance with their holdings of Series A Convertible Preferred Stock, and (iii) extend the expiration of the Warrants by one year, from November 3, 2026 to November 3, 2027, and each of Investor A and Investor B agreed to immediately thereafter convert its shares of Series A Convertible Preferred Stock to shares of Common Stock.
• REMARKS: Michael Simanovsky, Conversant Capital's Managing Partner, and Robert T. Grove, a Principal of Conversant Capital, serve as members of the Issuer's board of directors. On the basis of the relationship between Messrs. Simanovsky and Grove and the Reporting Person, the Reporting Person may be considered a director of the Issuer for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.